Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma

Trial Profile

Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Nov 2016

At a glance

  • Drugs Anti-CD20-CAR-transduced T cells (Primary)
  • Indications B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Beijing Biohealthcare Biotechnology
  • Most Recent Events

    • 23 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top